Start Date
January 31, 2008
Primary Completion Date
September 30, 2010
Study Completion Date
November 30, 2010
Fondaparinux
Arixtra 2.5 mg by subcutaneous injection once daily for 8 weeks or until disease recurrence or grade 3, 4 adverse events.
NYU Cancer Institute Clinical Cancer Center, New York
Collaborators (1)
GlaxoSmithKline
INDUSTRY
NYU Langone Health
OTHER